Hot Investor Mandate: Subsidiary of Korean Pharmaceutical Seeks to Partner and Invest in Oncology & Metabolic Disease Therapeutics

31 Jan

A wholly-owned subsidiary of a pharmaceutical and chemical company headquartered in Seoul, South Korea with offices in the USA is actively seeking promising compounds for innovative new drugs that have global market potential. The firm seeks to partner with companies in a wide variety of ways, including licensing, equity investment, joint venture development, etc. depending on the opportunity and strategic fit. The firm is focused on USA-based opportunities.

The firm is focused only on therapeutics, and does not invest in devices, diagnostics, or digital health companies. The firm is most interested in first-in-class (or best-in-class) assets in oncology/immuno-oncology, NASH and other metabolic diseases. The firm is focused on early-stage opportunities, and prefers to invest equity into partnered companies for R&D collaboration.

The firm does not have specific management team requirements and is open to working with all types of management teams. The firm can either lead or co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: